Literature DB >> 14676265

Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost.

M Emmel1, B Keuth, S Schickendantz.   

Abstract

The case of a 14 month old girl with primary pulmonary hypertension treated with domiciliary oxygen is described. After invasive evaluation and testing of nitric oxide with very good response, the testing was repeated to study the effect of inhaled iloprost on pulmonary vascular resistance (PVR). An unexpected and severe increase of PVR was observed, rising from 392 dynes x s x cm(-5) with oxygen to a maximum of 1192 dynes x s x cm(-5) with oxygen and iloprost. Underlying ventilatory and technical problems were excluded. While inhaled iloprost has been described to be highly effective in the treatment of primary pulmonary hypertension, the possibility of contrary "paradoxical" reactions in isolated patients is emphasised, with a dramatic increase of PVR and a possible adverse outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14676265      PMCID: PMC1768033          DOI: 10.1136/heart.90.1.e2

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Progress in, and future prospects for, the treatment of primary pulmonary hypertension.

Authors:  M R Wilkins; J Wharton
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

2.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 3.  New and experimental therapies for pulmonary hypertension.

Authors:  R N Channick; L J Rubin
Journal:  Clin Chest Med       Date:  2001-09       Impact factor: 2.878

4.  Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue.

Authors:  C D Vizza; S Sciomer; S Morelli; C Lavalle; P Di Marzio; D Padovani; R Badagliacca; A R Vestri; R Naeije; F Fedele
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 5.  Medical therapy of pulmonary hypertension. The prostacyclins.

Authors:  N Galié; A Manes; A Branzi
Journal:  Clin Chest Med       Date:  2001-09       Impact factor: 2.878

6.  Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion.

Authors:  M Beghetti; M Berner; P C Rimensberger
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 7.  Current management of primary pulmonary hypertension.

Authors:  E S Klings; H W Farber
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Authors:  O Sitbon; M Humbert; J L Jagot; O Taravella; M Fartoukh; F Parent; P Herve; G Simonneau
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

9.  Primary pulmonary hypertension in children: clinical characterization and survival.

Authors:  J Sandoval; O Bauerle; A Gomez; A Palomar; M L Martínez Guerra; M E Furuya
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

10.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

Authors:  S Rich; B H Brundage
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

  10 in total
  1 in total

1.  The effect of iloprost and sildenafil, alone and in combination, on myocardial ischaemia and nitric oxide and irisin levels.

Authors:  Suna Aydin; Tuncay Kuloglu; Suleyman Aydin; Meltem Yardim; Davut Azboy; Zeki Temizturk; Ali Kemal Kalkan; Mehmet Nesimi Eren
Journal:  Cardiovasc J Afr       Date:  2017-08-31       Impact factor: 1.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.